Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study

Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study

Abstract Anti-angiogenesis offers an important treatment strategy for metastatic breast cancer (MBC). Metronomic chemotherapy (MCT) provides antiangiogenic effects without increased toxicities, making it good partner for antiangiogenic therapy. We conducted the present retrospective study to evaluat...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiaxuan Liu, Jiayang Zhang, Huiping Li, Guohong Song, Lijun Di, Hanfang Jiang, Ying Yan, Huan Wang, Jing Wang, Xiaoran Liu, Bin Shao, Qiao Li
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Cancer
Subjects:
Metastatic breast cancer
Anlotinib
Metronomic chemotherapy
Anti-angiogenesis
Safety
Online Access:https://doi.org/10.1186/s12885-024-13403-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-024-13403-2

Similar Items